TP53突变骨髓增生异常综合征的基因组背景与等位基因频率定义临床结局
该研究评估了261例TP53突变MDS患者的临床病理特征、治疗反应与预后,中位年龄68岁,83%有复杂核型。TP53缺失与较低总缓解率相关,TP53 VAF每增加1%与更差预后独立相关。整合TP53 VAF与核型复杂性及IPSS-R参数的多变量模型可将患者分为4个预后亚组,中位生存期分别为未达到、42.2、21.9和9.2个月。
要点
- TP53缺失与HMA治疗总缓解率降低独立相关。
- TP53 VAF较低与HMA治疗总缓解率较高相关。
- 整合TP53 VAF与IPSS-R参数的模型可区分4个预后亚组。
核心结论
- TP53突变MDS患者结局异质,整合TP53 VAF与核型复杂性及IPSS-R参数可识别不同预后亚组。
研究设计与样本
- 回顾性评估261例TP53突变MDS患者的临床病理特征、治疗反应与预后。
- 中位年龄68岁(范围18-80岁),217例(83%)为复杂核型。
主要发现
- TP53 VAF较低与HMA治疗总缓解率较高相关。
- 13例(61%)在转化时TP53 VAF升高,15例(65%)出现既往不可检测的突变。
- 多变量模型识别4个预后亚组,中位生存期分别为未达到、42.2、21.9和9.2个月。
关键数值与推荐
- 总评分计算公式:VAF TP53 + 13×IPSS-R原始细胞评分 + 16×IPSS-R细胞遗传学评分 + 28×IPSS-R血红蛋白评分 + 46×IPSS-R血小板评分。
临床怎么用
- 对TP53突变MDS患者应评估TP53 VAF、TP53缺失状态及核型复杂性以进行预后分层。
- 可考虑使用整合TP53 VAF与IPSS-R参数的多变量模型辅助临床决策。
局限性
- 回顾性研究设计,样本量有限(261例),结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TP53 mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53 mutations in response outcomes and prognosis of MDS. We evaluated the clinicopathologic characteristics, outcomes, and response to therapy of 261 patients with MDS and TP53 mutations. Median age was 68 years (range, 18-80 years). A total of 217 patients (83%) had a complex karyotype. TP53 mutations were detected at a median variant allele frequency (VAF) of 0.39 (range, 0.01-0.94). TP53 deletion was associated with lower overall response rate (ORR) (odds ratio, 0.3; P = .021), and lower TP53 VAF correlated with higher ORR to HMAs. Increase in TP53 VAF at the time of transformation was observed in 13 patients (61%), and previously undetectable mutations were observed in 15 patients (65%). TP53 VAF was associated with worse prognosis (hazard ratio, 1.02 per 1% VAF increase; 95% confidence interval, 1.01-1.03; P < .001). Integration of TP53 VAF and karyotypic complexity identified prognostic subgroups within TP53-mutant MDS. We developed a multivariable model for overall survival that included the revised International Prognostic Scoring System (IPSS-R) categories and TP53 VAF. Total score for each patient was calculated as follows: VAF TP53 + 13 × IPSS-R blast score + 16 × IPSS-R cytogenetic score + 28 × IPSS-R hemoglobin score + 46 × IPSS-R platelet score. Use of this model identified 4 prognostic subgroups with median survival times of not reached, 42.2, 21.9, and 9.2 months. These data suggest that outcomes of patients with TP53-mutated MDS are heterogeneous and that transformation may be driven not only by TP53 but also by other factors.
引用
- Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020. PMID: 32027746. doi:10.1182/bloodadvances.2019001101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。